କାନାଗ୍ଲିଫ୍ଲୋଜିନ

କାନାଗ୍ଲିଫ୍ଲୋଜିନ
Clinical data
Pronunciation	/ˌkænəɡlɪˈfloʊzɪn/ KAN-ə-glif-LOH-zin
Trade names	Invokana, Sulisent, Prominad, others
AHFS/Drugs.com	monograph
MedlinePlus	a613033
data	EU EMA: yes; US DailyMed: Canagliflozin;
Pregnancy; category	US: C (Risk not ruled out) ; ;
Routes of; administration	By mouth (tablets)
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ; ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	65%
Protein binding	99%
Metabolism	Liver glucuronidation
Elimination half-life	11.8 (10–13) hours
Excretion	53% faecal and 33% kidney
Identifiers
	IUPAC name (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol;
ECHA InfoCard	100.223.671
Chemical and physical data
Formula	C24H25FO5S
Molar mass	୪୪୪.୫୨ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1ccc(cc1Cc2ccc(s2)c3ccc(cc3)F)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O;
	InChI InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1 ; Key:XTNGUQKDFGDXSJ-ZXGKGEBGSA-N ;

କାନାଗ୍ଲିଫ୍ଲୋଜିନ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବେପାର ନାମ ଇନଭୋକାନା, ଏକ ଔଷଧ ଯାହା ଟାଇପ୍-୨ ମଧୁମେହର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୧] ମେଟଫର୍ମିନ୍ ପାଇଁ ଏହା ଏକ ତୃତୀୟ ଧାଡି ଔଷଧ | ^[୨] ବ୍ୟାୟାମ ଏବଂ ଉପ‌ଯୁକ୍ତ ଖାଦ୍ୟ ସହିତ ଏହା ଏକତ୍ର ବ୍ୟବହୃତ ହୁଏ | ^[୩] ଟାଇପ୍ 1 ଡାଇବେଟିସ୍ରେ ଏହା ସୁପାରିଶ କରାଯାଏ ନାହିଁ | ^[୩] ଏହା ପାଟିରେ ଦିଆଯାଏ | ^[୩]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଯୋନୀପଥ ଇଷ୍ଟ ସଂକ୍ରମଣ, ବାନ୍ତି, କୋଷ୍ଠକାଠିନ୍ୟ ଏବଂ ମୂତ୍ରନଳୀ ସଂକ୍ରମଣ ହୋଇପାରେ | ^[୧] ଗୁରୁତର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିମ୍ନ ରକ୍ତ ଶର୍କରା, ଫୋରନିଅର ଗାଙ୍ଗ୍ରିନ, ଗୋଡ ଆମ୍ପୁଟେସନ, ବୃକ୍‌କ ସମସ୍ୟା, ଉଚ୍ଚ ରକ୍ତ ପୋଟାସିୟମ୍ ଏବଂ ନିମ୍ନ ରକ୍ତଚାପ ହୋଇପାରେ |^[୩] ରକ୍ତରେ ସାଧାରଣ ଶର୍କରା ସ୍ତର ଥିବା ସତ୍ତ୍ୱେ ମଧୁମେହ କେଟୋଏସିଡୋସିସ୍ ହୋଇପାରେ । ^[୩] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କରିବା ଏବଂ ସ୍ତନ୍ୟପାନ କରାଇବା ସୁପାରିଶ କରାଯାଏ ନାହିଁ | ^[୪] କାନାଗ୍ଲିଫୋଜିନ ହେଉଛି ଏକ ସୋଡିୟମ୍-ଗ୍ଲୁକୋଜ୍ କୋଟ୍ରାନ୍ସପୋର୍ଟର୍ 2 (SGLT2) ପ୍ରତିବନ୍ଧକ | ^[୩] ପରିସ୍ରାରେ ନଷ୍ଟ ହେଉଥିବା ଗ୍ଲୁକୋଜର ପରିମାଣ ଏହା ବୃଦ୍ଧି କରି କାର୍ଯକ୍ଷମ ହୁଏ | ^[୩]

୨୦୧୩ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ କାନାଗ୍ଲିଫୋଜିନକୁ ଅନୁମୋଦନ କରାଯାଇଥିଲା । ^[୧] ବ୍ରିଟେନରେ ୨୦୧୯ରେ ଏକ ମାସର ଯୋଗାଣ ମୂଲ୍ୟ ୩୯ ପାଉଣ୍ଡ ଥିଲା । ^[୨] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ହୋଲସେଲ ମୂଲ୍ୟ ପ୍ରାୟ ୪୭୫ ଡଲାର ଅଟେ । ^[୫] ୨୦୧୭ରେ, ଏହା ଆମେରିକାର ୧୯୨ତମ ସାଧାରଣ ପ୍ରେସକ୍ରିପସନ୍ ଔଷଧ ଥିଲା, ଯେଉଁଥିରେ ତିନି ଲକ୍ଷରୁ ଅଧିକ ପ୍ରେସକ୍ରିପସନ୍ ରହିଥିଲା | ^[୬] ^[୭]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ "Canagliflozin Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 6 April 2019. Retrieved 6 April 2019.
↑ ^୨.୦ ^୨.୧ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 687. ISBN 9780857113382.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ ^୩.୬ "Canagliflozin Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 6 April 2019. Retrieved 6 April 2019.
↑ "Canagliflozin (Invokana) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 6 April 2019. Retrieved 6 April 2019.
↑ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.
↑ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
↑ "Canagliflozin - Drug Usage Statistics". ClinCalc. Archived from the original on 13 April 2020. Retrieved 11 April 2020.

[AHFS2019-1] ୧.୦ ^୧.୧ ^୧.୨ "Canagliflozin Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 6 April 2019. Retrieved 6 April 2019.

[BNF76-2] ୨.୦ ^୨.୧ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 687. ISBN 9780857113382.

[autogen1-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ ^୩.୬ "Canagliflozin Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 6 April 2019. Retrieved 6 April 2019.

[4] "Canagliflozin (Invokana) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 6 April 2019. Retrieved 6 April 2019.

[NADAC2019-5] "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.

[ref-6] "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.

[ref1-7] "Canagliflozin - Drug Usage Statistics". ClinCalc. Archived from the original on 13 April 2020. Retrieved 11 April 2020.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

Clinical data

Pronunciation	/ˌkænəɡlɪˈfloʊzɪn/ KAN-ə-glif-LOH-zin
Trade names	Invokana, Sulisent, Prominad, others
AHFS/Drugs.com	monograph
MedlinePlus	a613033
data	EU EMA: yes US DailyMed: Canagliflozin
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	By mouth (tablets)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	65%
Protein binding	99%
Metabolism	Liver glucuronidation
Elimination half-life	11.8 (10–13) hours
Excretion	53% faecal and 33% kidney
Identifiers
IUPAC name (2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol
ECHA InfoCard	100.223.671
Chemical and physical data
Formula	C₂₄H₂₅FO₅S
Molar mass	୪୪୪.୫୨ g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES Cc1ccc(cc1Cc2ccc(s2)c3ccc(cc3)F)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
InChI InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1^N Key:XTNGUQKDFGDXSJ-ZXGKGEBGSA-N^N